Metacrine Inc. (MTCR)
NASDAQ: MTCR
· Real-Time Price · USD
0.58
-0.01 (-1.53%)
At close: Jun 20, 2023, 9:11 PM
Company Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases.
It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis.
Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine Inc.
| Country | United States |
| IPO Date | Sep 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | David M. Maggio |
Contact Details
Address: 3985 Sorrento Valley Boulevard San Diego, California United States | |
| Website | https://www.metacrine.com |
Stock Details
| Ticker Symbol | MTCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001634379 |
| CUSIP Number | 59101E103 |
| ISIN Number | US59101E1038 |
| Employer ID | 47-2297384 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David M. Maggio | Chief Bus. Officer, Pres, Chief Executive Officer, Sec., Treasurer, Principal Financial & Acct. Officer |
| Dr. Preston S. Klassen M.D., M.H.S. | Pres, Chief Executive Officer & Director |
| Michael B. York | Chief Bus. Officer, Pres, Chief Executive Officer, Sec., Treasurer, Principal Financial & Acct. Officer |
| Patricia Millican | Chief Financial Officer |
| Theresa Lowry | Vice President of HR |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2023 | 15-12G | Filing |
| Mar 24, 2023 | 8-K | Current Report |
| Mar 24, 2023 | 4 | Filing |
| Mar 23, 2023 | S-8 POS | Filing |
| Mar 23, 2023 | S-8 POS | Filing |
| Mar 23, 2023 | 8-K | Current Report |
| Mar 15, 2023 | 8-K | Current Report |
| Mar 03, 2023 | POS AM | Filing |
| Mar 03, 2023 | 8-K | Current Report |
| Mar 03, 2023 | 25-NSE | Filing |